Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 60.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,865 shares of the company’s stock after selling 12,191 shares during the quarter. Voya Investment Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $305,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Arrowstreet Capital Limited Partnership bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $20,349,000. Qube Research & Technologies Ltd increased its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after buying an additional 651,700 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after buying an additional 447,536 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Up 1.8%

Shares of KNSA stock opened at $42.01 on Monday. The stock has a 50-day simple moving average of $40.88 and a 200 day simple moving average of $35.93. The stock has a market capitalization of $3.18 billion, a P/E ratio of 93.36 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. Kiniksa Pharmaceuticals International’s revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) earnings per share. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the completion of the sale, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This trade represents a 46.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the transaction, the chief operating officer owned 16,666 shares in the company, valued at $692,638.96. The trade was a 41.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 511,057 shares of company stock valued at $19,972,512. Corporate insiders own 53.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on KNSA shares. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Citigroup raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Wedbush reiterated an “outperform” rating and issued a $48.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.